Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Regenerative Medicine Laws Take Effect, Encourage Industry

This article was originally published in PharmAsia News

Executive Summary

Japan has formally enacted new legislation governing the development, approval and use of regenerative medicines, including induced pluripotent stem (iPS) cells, in a move welcomed by companies both inside and outside the country.

You may also be interested in...



Dainippon Partnership Rejig Helps Healios Focus Resources

Big pharma partner takes on prime development responsibility for novel AMD cell therapy as Japanese venture concentrates resources on other in-progress trials.

Japan's Healios Progresses Novel Cell Therapy For ARDS

Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.

Japan’s Healios Eyes First Approvals As It Progresses Regenerative Therapies

Healios, a Japanese regenerative medicine bioventure, expects to continue benefiting from a supportive regulatory environment in Japan as it progresses three clinical assets toward approval in the next few years, says CEO Dr. Hardy Kagimoto in an exclusive interview.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel